PD-1 Pathway Inhibitor Small Molecules for Oral Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for modulating the PD-1 pathway, particularly for cancer therapy, rely heavily on antibodies, with a need for alternative small molecules that offer advantages in oral administration, stability, bioavailability, and toxicity profile.
Innovation Solution
Development of novel compounds with specific structural formulas that act as inhibitors of the PD-1/PD-L1 pathway, including pharmaceutical compositions and methods for their preparation and use in therapeutic treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-based therapies are used to block the PD-1 pathway, then therapeutic efficacy against cancer is achieved, but administration complexity and cost increase
Solution Approach 1:
The patent replaces the mechanical/administrative complexity of antibody delivery (intravenous infusion, cold chain storage, injection equipment) with small molecule compounds that can be administered orally as pills or capsules. This substitution maintains the biological therapeutic effect while eliminating the mechanical delivery system complexities.
Solution Approach 2:
The invention changes the chemical parameter of the therapeutic agent from large protein-based antibodies to small organic molecules. This parameter change enables different administration routes (oral vs. parenteral), different storage conditions, and different pharmacokinetic profiles, thereby improving ease of operation while maintaining efficacy.
2Reliability
If antibody-based therapies are used to block the PD-1 pathway, then immune response is enhanced, but production cost and device complexity increase
Solution Approach 1:
The patent substitutes the complex biomanufacturing process required for antibodies (cell culture, purification, formulation, cold chain logistics) with small molecule synthesis processes that are more standardized, scalable, and less equipment-intensive. This reduces device complexity in manufacturing while preserving the immune response enhancement effect.
Solution Approach 2:
The invention changes the manufacturing parameter from biologics production (requiring GMP-certified cell culture facilities, specialized equipment, and complex quality control) to small molecule synthesis (using established chemical manufacturing processes). This parameter change simplifies the manufacturing device complexity while maintaining therapeutic reliability.
3Ease of operation
If alternative small molecules are developed, then oral administration and stability are improved, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex task of small molecule design into manageable components: identifying the target binding pocket, selecting scaffold structures, optimizing pharmacophore elements, and refining pharmacokinetic properties. This segmented approach makes the overall development process more systematic and less overwhelming.
Solution Approach 2:
The invention employs preliminary action by pre-selecting candidate scaffold structures and pharmacophore elements before full optimization. Computational modeling and in silico screening are performed in advance to identify promising candidates, reducing the complexity of subsequent experimental development and streamlining the path to oral administration-capable molecules.
Data Source
AI summary
Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.